Shares of Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) shot up 1.5% on Thursday . The stock traded as high as $5.15 and last traded at $4.76. 56,094 shares changed hands during trading, a decline of 92% from the average session volume of 693,561 shares. The stock had previously closed at $4.69.
Analyst Upgrades and Downgrades
Separately, Maxim Group restated a “buy” rating and set a $22.50 price objective on shares of Palisade Bio in a report on Wednesday, May 1st.
Get Our Latest Stock Report on PALI
Palisade Bio Trading Up 1.5 %
Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($4.59) EPS for the quarter. As a group, equities research analysts predict that Palisade Bio, Inc. will post -10.81 EPS for the current year.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Read More
- Five stocks we like better than Palisade Bio
- Investing in Commodities: What Are They? How to Invest in Them
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- What does consumer price index measure?
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.